Fortress Biotech Q1 net income $108.4M; PRV sale for $205M and ZYCUBO approval drive results

Fortress Biotech, Inc.

Net income $108.4M ($3.44 basic EPS) vs net loss $12.7M in Q1 2025; revenue $16.0M up from $13.1M.
Subsidiary Cyprium sold Rare Pediatric Disease PRV for $205M in March 2026; ZYCUBO approved for Menkes disease.
Debt reduced: prepaid Oaktree loan to $15M outstanding; cash increased to $255.8M from $79.4M.
Checkpoint acquisition by Sun Pharma gives Fortress ~$28M upfront + 2.5% royalty on UNLOXCYT sales.
Journey Medical's Emrosi launched; payer access expanded to 85% of US commercial lives.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.